0

530317

GODAVARI

img img img img
No Data Available

GODAVARI DRUGS LTD. Share Price Update

As of the latest trading session, GODAVARI DRUGS LTD. is trading at ₹127.95, down by ₹-0.25 or -0.19% from its previous close. The stock has moved between ₹126.00 and ₹128.00 today. Over the past year, the stock has delivered a return of 36.39%. In the last month, it has returned 21.51%.

Investment Returns

Over 1 Month 21.51% Over 3 Months 45.36% Over 6 Months 56.87% Over 1 Year 36.39%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

GODAVARI DRUGS LTD. fundamentals


  • Market cap (Cr) [-]
  • P/E Ratio (TTM) [-]
  • Beta [-]
  • Book Value / share [-]
  • Return on equity [-]%
  • EPS (TTM) [-]
  • Dividend yield [-]%
  • Net profit/quarter (Cr) [-]
info icon alternate text
  • Market cap (Cr) 129.60
  • P/E Ratio (TTM) 29.68
  • Beta 0.79
  • Book Value / share 65.62
  • Return on equity 10.64%
  • EPS (TTM) 4.30
  • Dividend yield [-]%
  • Net profit/quarter (Cr) 0.76
info icon alternate text

GODAVARI DRUGS LTD. Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars DEC 2025 (Values in Cr)
Revenue 22.18
Operating Expense 21.43
Net Profit 0.76
Net Profit Margin (%) 3.42
Earnings Per Share (EPS) 1.01
EBITDA 2.73
Effective Tax Rate (%) 25.49
Particulars SEP 2025 (Values in Cr)
Revenue 26.65
Operating Expense 26.17
Net Profit 1.00
Net Profit Margin (%) 3.75
Earnings Per Share (EPS) 1.33
EBITDA 2.63
Effective Tax Rate (%) 10.71
Particulars JUN 2025 (Values in Cr)
Revenue 23.81
Operating Expense 22.52
Net Profit 1.04
Net Profit Margin (%) 4.36
Earnings Per Share (EPS) 1.38
EBITDA 2.90
Effective Tax Rate (%) 20.00
Particulars MAR 2025 (Values in Cr)
Revenue 25.50
Operating Expense 24.16
Net Profit 0.89
Net Profit Margin (%) 3.49
Earnings Per Share (EPS) 1.19
EBITDA 3.21
Effective Tax Rate (%) 38.19
Particulars DEC 2024 (Values in Cr)
Revenue 29.55
Operating Expense 28.73
Net Profit 0.77
Net Profit Margin (%) 2.60
Earnings Per Share (EPS) 1.02
EBITDA 2.67
Effective Tax Rate (%) 16.30
Particulars MAR 2025 (Values in Cr)
Revenue 113.35
Operating Expense 108.70
Net Profit 4.38
Net Profit Margin (%) 3.86
Earnings Per Share (EPS) 5.82
EBITDA 12.80
Effective Tax Rate (%) 22.20
Particulars MAR 2024 (Values in Cr)
Revenue 156.71
Operating Expense 150.32
Net Profit 5.55
Net Profit Margin (%) 3.54
Earnings Per Share (EPS) 7.37
EBITDA 13.83
Effective Tax Rate (%) 19.79
Particulars MAR 2023 (Values in Cr)
Revenue 159.62
Operating Expense 155.58
Net Profit 3.79
Net Profit Margin (%) 2.37
Earnings Per Share (EPS) 5.03
EBITDA 10.79
Effective Tax Rate (%) 23.32
Particulars MAR 2022 (Values in Cr)
Revenue 161.11
Operating Expense 154.35
Net Profit 5.25
Net Profit Margin (%) 3.25
Earnings Per Share (EPS) 6.97
EBITDA 11.56
Effective Tax Rate (%) 25.35
Particulars MAR 2021 (Values in Cr)
Revenue 122.67
Operating Expense 117.38
Net Profit 4.13
Net Profit Margin (%) 3.36
Earnings Per Share (EPS) 5.48
EBITDA 10.24
Effective Tax Rate (%) 27.67
Particulars MAR 2025 (Values in Cr)
Book Value / Share 57.56
ROE % 10.64
ROCE % 10.06
Total Debt to Total Equity 1.48
EBITDA Margin 11.29
Particulars MAR 2024 (Values in Cr)
Book Value / Share 51.74
ROE % 15.33
ROCE % 14.14
Total Debt to Total Equity 1.29
EBITDA Margin 8.83
Particulars MAR 2023 (Values in Cr)
Book Value / Share 44.38
ROE % 12.02
ROCE % 14.37
Total Debt to Total Equity 0.93
EBITDA Margin 6.77
Particulars MAR 2022 (Values in Cr)
Book Value / Share 39.35
ROE % 19.44
ROCE % 18.12
Total Debt to Total Equity 0.99
EBITDA Margin 7.18
Particulars MAR 2021 (Values in Cr)
Book Value / Share 32.38
ROE % 18.50
ROCE % 17.34
Total Debt to Total Equity 1.30
EBITDA Margin 8.36
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 2.37
Total Assets 143.07
Total Liabilities 143.07
Total Equity 43.34
Share Outstanding 0
Price to Book Ratio 1.52
Return on Assets (%) 3.06
Return on Capital (%) 4.17
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 2.62
Total Assets 134.75
Total Liabilities 134.75
Total Equity 38.96
Share Outstanding 0
Price to Book Ratio 1.80
Return on Assets (%) 4.11
Return on Capital (%) 5.87
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3.08
Total Assets 121.43
Total Liabilities 121.43
Total Equity 33.41
Share Outstanding 0
Price to Book Ratio 1.71
Return on Assets (%) 3.11
Return on Capital (%) 5.66
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.27
Total Assets 101.41
Total Liabilities 101.41
Total Equity 29.63
Share Outstanding 0
Price to Book Ratio 1.66
Return on Assets (%) 5.17
Return on Capital (%) 10.5
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.63
Total Assets 91.13
Total Liabilities 91.13
Total Equity 24.38
Share Outstanding 0
Price to Book Ratio 1.41
Return on Assets (%) 4.52
Return on Capital (%) 7.87
Particulars MAR 2025 (Values in Cr)
Net Income 12.80
Cash from Operations 12.35
Cash from Investing -19.51
Cash from Financing 8.06
Net change in Cash -0.24
Free Cash Flow 32.34
Particulars MAR 2024 (Values in Cr)
Net Income 13.83
Cash from Operations 19.43
Cash from Investing -13.22
Cash from Financing -5.65
Net change in Cash -0.46
Free Cash Flow 32.63
Particulars MAR 2023 (Values in Cr)
Net Income 10.80
Cash from Operations 14.36
Cash from Investing -8.63
Cash from Financing -3.77
Net change in Cash 0.80
Free Cash Flow 23.66
Particulars MAR 2022 (Values in Cr)
Net Income 11.56
Cash from Operations 13.00
Cash from Investing -4.97
Cash from Financing -5.62
Net change in Cash 0.63
Free Cash Flow 18.25
Particulars MAR 2021 (Values in Cr)
Net Income 10.23
Cash from Operations 2.90
Cash from Investing -1.25
Cash from Financing 0.13
Net change in Cash 0.21
Free Cash Flow 4.57
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 32.34 14.00 1.67 247.83 23.12 40.44
BLISS GVS PHARMA LTD. 278.20 22.51 2.46 2943.05 117.20 293.15
CIPLA LTD 1431.55 28.35 3.35 115640.69 1165.55 1672.20
FERMENTA BIOTECH LIMITED 295.25 9.82 2.22 868.95 256.40 399.00
GLAXOSMITHKLINE PHARMA LT 2439.75 40.49 18.22 41330.84 2218.00 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 32.34 31.10 4.50 247.83 23.12 40.44
AMRUTANJAN HEALTH CARE LTD. 558.00 25.01 4.35 1613.21 490.00 789.95
ASTRAZENECA PHARMA IND LT 8488.45 102.01 26.55 21221.13 7630.00 10653.05
BLISS GVS PHARMA LTD. 278.20 29.91 2.54 2943.05 117.20 293.15

GODAVARI DRUGS LTD. shareholding pattern

Holding
57.3%
40.22%
2.46%
0.21%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

GODAVARI DRUGS LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
128.00 -0.15 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 127.60
  • 26 Days 117.90
  • 10 Days 126.10
  • 50 Days 108.30
  • 12 Days 125.30
  • 100 Days 98.90
  • 20 Days 121.10
  • 200 Days 94.10
128.13 PIVOT
First Support 125.77 First Resistance 130.57 Second Support 123.33 Second Resistance 132.93 Third Support 120.97 Third Resistance 135.37
RSI 63.93 ADX 56.34 MACD 7.36 Williams % R -26.14 Commodity Channel Index (CCI) 89.48
Date 2026-05-15 Week 9984.00 Same Day 6005.00 Month 15122.00
1 Year 0.80 3 Year 0.58
Over 1 Month
21.51% down
Over 1 Year
36.39% down
Over 3 Months
45.36% down
Over 3 Years
16.67% down
Over 6 Months
56.87% down
Over 5 Years
16.67% down

GODAVARI DRUGS LTD. Corporate Actions

Top Gainers

Top Losers

GODAVARI DRUGS LTD. Share Price

Godavari Drugs Limited is engaged in the business of manufacture of Active Pharmaceutical Ingredients (API) and drug intermediates and fine chemicals catering to global life science industry. It works a manufacturing plant at Nanded, Maharashtra, India. Sulphamethoxazole (SMX), the main product of the company, is a widely used anti-bacterial drug enjoying good export demand. Company apart from its own products, explores continual opportunities for loan licence manufacturing with reputed multinational companies.

The Company incorporated in December, 1987, has multiple production blocks for API's, drug intermediates and fine chemicals.

The company has expanded its SMX capacity from 540 tpa to 720 tpa, integrating backward into the manufacture of drug intermediates, sulphamethoxide (cap.: 450 tpa) and diethyl oxalate, DEO (cap.: 750 tpa), and diversifying into the manufacture of trimetroprim, TMP (cap.: 144 tpa).

The diversification into TMP is beneficial as SMX and TMP are used in combination to treat a wide variety of infections. The backward integration into SMO and DEO will enhance value-addition. In fact, Siris and Chemox Chemicals, both having good capacities of SMX, have recently gone in for the production of SMO.

In 2000 the company introduced 'Pyrazyamide' in the market. Since the product is being well accepted in the market the company is planning to increase the capacity of 'Pyrazyamide' of 180 TPA and have also finalised on other products Cislactum,which is a intermediate used to produce Diltiazem an anti anginal drug.

The Company is setting up API and intermediate manufacturing facility which is to be commissioned towards the end of the current financial year 2025-26.

Parent organization Indian Private
NSE symbol [-]
Founded 1987
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Godavari Drugs Ltd?

Answer Field

Godavari Drugs Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 128.00 as on May 18 2026 03:29 PM.

What is the Market Cap of Godavari Drugs Ltd Share?

Answer Field

The market cap of Godavari Drugs Ltd for NSE ₹ 0.00 & for BSE ₹ 129.60 as on May 18 2026 03:29 PM.

What is the 52 Week High and Low of Godavari Drugs Ltd?

Answer Field

The 52 Week High and Low of Godavari Drugs Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 134.50 and ₹ 69.70.

What is 1 year return for Godavari Drugs Ltd?

Answer Field

The 1 year returns on the stock has been 36.39%.

What is the P/E Ratio of Godavari Drugs Ltd Share?

Answer Field

As on May 18 2026 03:29 PM the price-to-earnings (PE) ratio for Godavari Drugs Ltd share is 29.68.

What is the PB ratio of Godavari Drugs Ltd Share?

Answer Field

As on May 18 2026 03:29 PM, the price-to-book (PB) ratio for Godavari Drugs Ltd share is 65.62.

How to Buy Godavari Drugs Ltd Share?

Answer Field

You can trade in Godavari Drugs Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Godavari Drugs Ltd Share on Bajaj Broking App?

Answer Field

To buy Godavari Drugs Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Godavari Drugs Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|